Weekly longevity roundup: centenarian gut enzyme, blood NAD, steps and mortality, and partial reprogramming
A weekly digest covers a centenarian gut enzyme tested in aged mice, blood NAD tied to heart health, step counts, brain training and reprogramming safety signals.
Summary
This EurekAlert digest for November 13-19, 2026 gathers several longevity findings. UC San Diego researchers found higher bile-salt hydrolase activity in centenarians' gut bacteria and engineered bacteria to reproduce it in aged mice, which improved insulin sensitivity, body composition, mitochondrial function and inflammation-related gene activity. Lifespan and human benefit were not shown. A Mayo Clinic Proceedings review found physical activity and fitness more strongly linked to lower mortality than diet quality. A Nature Metabolism study of 1,068 adults found whole-blood NAD did not fall with age in healthy people but was lower in cardiovascular disease. A Lumosity trial improved cognitive test scores. Partial reprogramming in aged mice showed benefits in liver and kidney but concerning signals in spleen. The digest is a summary of reports, not the original studies.
Detailed Summary
Why this matters: Longevity science moves quickly, and a single week can bring mechanisms, observational signals and cautionary findings together. This digest from EurekAlert, covering November 13-19, 2026, collects seven items, and each needs to be read at its own evidence level.
The most mechanistic item comes from UC San Diego. Researchers found increased bile-salt hydrolase activity in the gut microbiome of centenarians, then engineered gut bacteria to reproduce this activity in aged mice. Treated mice showed better insulin sensitivity, body composition, mitochondrial function and inflammation-related gene activity. These are mechanism and function results in mice. A lifespan benefit and any human therapeutic effect have not been established.
Human data point in other directions. A Mayo Clinic Proceedings review, drawing on meta-analyses, reported stronger associations of physical activity and cardiorespiratory fitness with lower all-cause mortality than diet quality. About 11,000-16,000 daily steps were associated with 45%-67% lower mortality than roughly 2,000-5,000 steps. These are associations. A Nature Metabolism study of 1,068 adults found whole-blood NAD did not decline with age in healthy participants, but was lower in people with cardiovascular disease, especially hypertension. That challenges the assumption that blood NAD decline with age universally supports supplementation.
An 801-person randomized trial found 12 weeks of Lumosity training improved a 12-test cognitive battery more than educational videos. Exploratory analyses in adults aged 60-80 suggested more favorable brain-predicted aging and imaging measures. Dementia prevention and lifespan extension were not shown.
In mice, partial in-vivo reprogramming produced potentially beneficial molecular changes in liver and kidney but concerning signals in spleen; the analysis was small and secondary. TMEM174 deficiency in animals caused phosphate dysregulation, vascular calcification and shortened lifespan, partly mitigated by lower dietary phosphate. A new method to isolate human thymic epithelial cells may support thymus research.
Caveats: This is a secondhand digest based on the abstract only, so design details are limited.
Key Findings
- Centenarian-like bile-salt hydrolase activity engineered into aged mouse gut improved insulin sensitivity, mitochondrial function and body composition; lifespan and human effects not shown.
- Review of meta-analyses linked physical activity and fitness to lower mortality more strongly than diet quality; 11,000-16,000 steps daily tracked with 45%-67% lower risk.
- In 1,068 adults, whole-blood NAD did not fall with age in healthy people but was lower in cardiovascular disease, especially hypertension.
- Partial reprogramming in aged mice showed liver and kidney benefits but concerning spleen signals, in a small secondary analysis.
- Lumosity training improved cognitive test scores in 801 people; dementia prevention and lifespan effects were not demonstrated.
Methodology
This is a press-release digest summarizing multiple studies: a mouse microbiome intervention, a review of meta-analyses, a 1,068-person cross-sectional NAD study, an 801-person randomized trial, and animal and cell work. Evidence levels differ across items, and only digest-level details are available.
Study Limitations
This summary is based on the abstract only, a secondhand digest rather than the original papers, so sample details, effect sizes and confounder control are unavailable. Several findings are animal, associational or exploratory, and lifespan and human efficacy were not shown for the mechanistic items. Partial reprogramming raised spleen safety concerns.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
